SLEek

Inclusion Criteria:

- Participant has clinical diagnosis of SLE at least 24 weeks prior to screening,
meeting at least 4 of the 11 revised Criteria for Classification of SLE according to
the 1997 Update of the 1982 American College of Rheumatology (ACR) OR meeting at least
4 of the 2012 SLICC classification criteria, including at least 1 clinical criterion
and 1 immunologic criterion.

- At Screening, must have at least one of the following:

- antinuclear antibody(ANA)+ (titer >= 1:80).

- anti-dsDNA+.

- anti-Smith+.

- SLEDAI-2K >= 6 despite background therapy as reported and independently adjudicated
(clinical score >= 4, excluding lupus headache and/or organic brain syndrome) at
Screening.

- If 4 points of the required entry points are for arthritis, there must also be a
minimum of 3 tender and 3 swollen joints.

- If participant has rash and PI considers it to be attributable to SLE,
participant must consent to skin photograph collection for adjudication.

- Score must be re-confirmed at the Baseline visit.

- Physician's Global Assessment (PhGA) >= 1 during screening period.

- Must be on background treatment, stable for 30 days, at Baseline and throughout the
study with antimalarial(s), prednisone (or prednisone equivalent) (<=20 mg),
azathioprine (<= 150 mg), mycophenolate (<2 g), leflunomide (<=20 mg), cyclosporine,
tacrolimus, and/or methotrexate (MTX) (<=20 mg).

- No combinations of the above with immunomodulators other than prednisone (or
equivalents) and antimalarials.

Exclusion Criteria:

- Participant using intravenous (IV) or intramuscular (IM) corticosteroids greater than or
equal to a 40 mg prednisone-equivalent bolus within 30 days of planned randomization.